Immunic, Inc. (IMUX) income statement
IMUXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$7.52+0.19 (+2.59%)
Close on Nov 18, 2026Market cap $102.61MP/E –Yield 0.00%
Immunic, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -1653.1%
Financial strength
- Current ratio
- 5.05
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 496.2%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.80
- Dividend yield
- 0.00%
See a number that looks wrong?